

Half-Yearly report on the liquidity contract With CM-CIC Securities

Paris, France, January 15, 2016

Pursuant to the liquidity contract entrusted by CELLNOVO to CM-CIC Securities, as of December 31, 2015, the following assets appeared on the liquidity account:

- **8,036** shares CELLNOVO
- Cash balance of the liquidity account: **€178,470.52**

As a reminder, when the contract was implemented, the following resources were booked to the liquidity account:

- Cash balance of the liquidity account: **€300,000**

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Consilium Strategic Communications

International Media Relations
Amber Fennell, Chris Gardner, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

